[go: up one dir, main page]

AU2001263217A1 - Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids - Google Patents

Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids

Info

Publication number
AU2001263217A1
AU2001263217A1 AU2001263217A AU6321701A AU2001263217A1 AU 2001263217 A1 AU2001263217 A1 AU 2001263217A1 AU 2001263217 A AU2001263217 A AU 2001263217A AU 6321701 A AU6321701 A AU 6321701A AU 2001263217 A1 AU2001263217 A1 AU 2001263217A1
Authority
AU
Australia
Prior art keywords
tetrahydrocannabinol
cell proliferation
delta8
methods
decreasing cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263217A
Inventor
Sumner Burstein
Lawrence Recht
Robert B. Zurier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001263217A1 publication Critical patent/AU2001263217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.
AU2001263217A 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids Abandoned AU2001263217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20493500P 2000-05-17 2000-05-17
US60204935 2000-05-17
PCT/US2001/015927 WO2001087296A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)δ8-tetrahydrocannabinol-11-oic acids

Publications (1)

Publication Number Publication Date
AU2001263217A1 true AU2001263217A1 (en) 2001-11-26

Family

ID=22760084

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2001264680A Ceased AU2001264680B2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU6169501A Pending AU6169501A (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
AU2001263217A Abandoned AU2001263217A1 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
AU6468001A Pending AU6468001A (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001261695A Ceased AU2001261695B2 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2001264680A Ceased AU2001264680B2 (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU6169501A Pending AU6169501A (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU6468001A Pending AU6468001A (en) 2000-05-17 2001-05-17 Cannabinoid drugs
AU2001261695A Ceased AU2001261695B2 (en) 2000-05-17 2001-05-17 Methods for decreasing cell proliferation based on (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Country Status (13)

Country Link
US (2) US6448288B1 (en)
EP (2) EP1307186A4 (en)
JP (2) JP2003533478A (en)
CN (2) CN1227007C (en)
AT (1) ATE406156T1 (en)
AU (5) AU2001264680B2 (en)
CA (2) CA2408961A1 (en)
DE (1) DE60135557D1 (en)
HU (2) HUP0700038A2 (en)
IL (3) IL152892A0 (en)
NZ (2) NZ523028A (en)
RU (2) RU2273476C2 (en)
WO (3) WO2001087297A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2004103410A1 (en) 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
JP2007501279A (en) * 2003-05-20 2007-01-25 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション Cannabinoid derivatives, methods for their production, and uses
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20060128794A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
US20070037873A1 (en) * 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
EP1928853A4 (en) * 2005-09-29 2011-02-16 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
WO2007047010A2 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (en) 2006-12-30 2008-07-31 Abbott Gmbh & Amp OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
EP2231644B1 (en) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases
CN101952276B (en) 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-Halogen-substituted oxindole derivatives and their use for the treatment of vasopressin-dependent diseases
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
EP2231643B1 (en) 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. STING THIOPHENE BENZO [B] AGONISTS FOR CANCER TREATMENT
CN111233814A (en) * 2020-03-02 2020-06-05 福建省中科生物股份有限公司 Terpene phenolic compound ZKYY-057 and preparation method and application thereof
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
ZA885929B (en) * 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US4880030A (en) * 1988-07-25 1989-11-14 Terry Paul E Safety flow control fluid shutoff device
US5635530A (en) * 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6162829A (en) * 1997-10-17 2000-12-19 Atlantic Pharmaceuticals, Inc. (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics
ES1045342Y (en) * 2000-02-11 2001-02-16 Alvarez Manuel Couto ROTATING EXHIBITOR FOR POSTCARDS, PHOTOS AND SIMILAR.

Also Published As

Publication number Publication date
RU2273476C2 (en) 2006-04-10
CN1227007C (en) 2005-11-16
US6448288B1 (en) 2002-09-10
NZ523029A (en) 2004-11-26
CN1452485A (en) 2003-10-29
AU2001264680B2 (en) 2006-09-14
EP1307188A1 (en) 2003-05-07
WO2001087295A1 (en) 2001-11-22
CN1273123C (en) 2006-09-06
WO2001087295A8 (en) 2003-04-10
NZ523028A (en) 2004-09-24
HUP0700039A2 (en) 2007-05-02
EP1307186A4 (en) 2005-10-19
US20020022653A1 (en) 2002-02-21
AU6468001A (en) 2001-11-26
CA2408961A1 (en) 2001-11-22
JP2003533478A (en) 2003-11-11
AU2001261695B2 (en) 2005-06-16
ATE406156T1 (en) 2008-09-15
EP1307188B1 (en) 2008-08-27
JP2003533479A (en) 2003-11-11
RU2272620C2 (en) 2006-03-27
WO2001087296A1 (en) 2001-11-22
CA2409005A1 (en) 2001-11-22
HUP0700038A2 (en) 2007-05-02
EP1307186A1 (en) 2003-05-07
IL152891A0 (en) 2003-06-24
US20040225011A1 (en) 2004-11-11
AU6169501A (en) 2001-11-26
EP1307188A4 (en) 2005-07-06
DE60135557D1 (en) 2008-10-09
US6914072B2 (en) 2005-07-05
IL152892A (en) 2010-06-30
WO2001087297A1 (en) 2001-11-22
IL152892A0 (en) 2003-06-24
CN1447685A (en) 2003-10-08

Similar Documents

Publication Publication Date Title
AU2001263217A1 (en) Methods for decreasing cell proliferation based on (3r, 4r)delta8-tetrahydrocannabinol-11-oic acids
WO2002053516A3 (en) N(phenylsulphonyl)glycine derivatives and their therapeutic use
AU2003237304A1 (en) Optical polarization beam combiner/splitter
AU2003213290A1 (en) Compound polarization beam splitters
AU2001273728A1 (en) Arrangement for connecting planar components
AU2001287156A1 (en) Treatment for high pressure bleeding
AU2002353128A1 (en) Bracing system for stringed instrument
AU2002316074A1 (en) System for quantifying edema
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2002357003A1 (en) Indoles as naaladase inhibitors
AU2002347970A1 (en) System integration for live-venue downloadable music
WO2004022029A3 (en) Branched alcohol-based personal care compositions
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2003274615A1 (en) Using configuration identifiers for communicating configuration descriptions
AU2001283161A1 (en) Pumping arrangement for fiber amplifiers
HUP0304079A3 (en) Carcass alignment system for carcass splitter
AU2001263786A1 (en) Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU3683700A (en) Database organization for increasing performance by splitting tables
AU2001288632A1 (en) N-way demultiplexer
AU2002351021A1 (en) Kit for reducing aching caused by pde-v inhibitors
AU2002220346A1 (en) Method for determination of the fertility of mammals, in particular of man
AU2002243647A1 (en) Novel mesogens
AU2002242942A1 (en) 3-0-'alfa-l-rhamnopyranosyl- (1-2) -alpha-l-rhamnopyranosyl- (1-4) -3beta-d-glucopyranosyl!-25 (s) -spirost an-3beta-ol, process for its isolation, and its use as immunomodulator
AU2003285636A1 (en) Birefringent optical component
AU2002250319A1 (en) Polarization combiner/splitter